公开(公告)号：US20220168293A1

公开(公告)日：2022-06-02

申请号：US17538919

申请日：2021-11-30

Applicant: PFIZER INC.

Inventor： Despoina Thomaidou

IPC: A61K31/4439 ,  C07K16/28 ,  A61P35/00

Abstract: This invention relates to a method of managing an adverse event in a renal cell carcinoma (RCC) patient undergoing treatment with axitinib, or a pharmaceutically acceptable salt thereof, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 1-7 days to allow the adverse event to resolve before restarting treatment. Additionally, the invention relates to a method of managing an adverse event in an RCC patient undergoing treatment with a combination of axitinib, or a pharmaceutically acceptable salt thereof, and an immune-oncology (IO) agent, wherein said method comprises interrupting axitinib, or a pharmaceutically acceptable salt thereof, treatment for at least 4-11 days to allow the adverse event to resolve before restarting axitinib, or a pharmaceutically acceptable salt thereof, treatment.

公开(公告)号：US20220142927A1

公开(公告)日：2022-05-12

申请号：US17580991

申请日：2022-01-21

Applicant: PFIZER INC.

Inventor： Scott Max Herbig ,  Sriram Krishnaswami ,  Joseph Kushner, IV ,  Manisha Lamba ,  Thomas C. Stock

IPC: A61K9/20 ,  A61K31/519 ,  A61K9/00

Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

公开(公告)号：US20220136020A1

公开(公告)日：2022-05-05

申请号：US17431462

申请日：2020-02-20

Applicant: Pfizer Inc.

Inventor： Ling Chu ,  Scott Andrew Cook ,  Nishith Merchant ,  Justin Keith Moran

IPC: C12P19/04 ,  B01D21/01 ,  B01D61/14 ,  B01D39/20

Abstract: The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides.

公开(公告)号：US20220125777A1

公开(公告)日：2022-04-28

申请号：US17427015

申请日：2020-01-31

Applicant: Pfizer Inc.

Inventor： Zhou Zhu ,  Yuan Liu

IPC: A61K31/4545 ,  A61K31/4196 ,  A61K31/566 ,  A61K31/565 ,  A61K31/519 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.

公开(公告)号：US11312713B2

公开(公告)日：2022-04-26

申请号：US16492558

申请日：2018-03-06

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Thomas Allen Chappie ,  Jinshan Michael Chen ,  Jotham Wadsworth Coe ,  Karen Jean Coffman ,  Paul Galatsis ,  Michelle Renee Garnsey ,  Christopher John Helal ,  Jaclyn Louise Henderson ,  Bethany Lyn Kormos ,  Ravi G. Kurumbail ,  Luis Angel Martinez-Alsina ,  Martin Youngjin Pettersson ,  Matthew Richard Reese ,  Colin Richard Rose ,  Antonia Friederike Stepan ,  Patrick Robert Verhoest ,  Travis T. Wager ,  Joseph Scott Warmus ,  Yuan Zhang

IPC: C07D471/04

Abstract: The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R1, R2 and R3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

公开(公告)号：US20220119545A1

公开(公告)日：2022-04-21

申请号：US17292257

申请日：2019-11-07

Applicant: Beth Israel Deaconess Medical Center ,  Pfizer Inc. ,  Cornell University

Inventor： Lewis C. CANTLEY ,  Stephen P. SOLTOFF ,  Brooke M. EMERLING ,  George POULOGIANNIS ,  Cindy M. HODAKOSKI ,  Hui LIU ,  Irina APOSTOLOU ,  Brian Gaither BATES ,  Kimberly Ann MARQUETTE ,  Eric M. BENNETT ,  Lidia MOSYAK ,  Lioudmila G. TCHISTIAKOVA ,  Edward Christian ROSFJORD ,  Isaac J. RONDON ,  Chao Bai HUANG

IPC: C07K16/28 ,  A61P35/00

Abstract: The present disclosure provides materials and methods for CUB domain-containing protein 1 (CDCP1)-targeted therapy.

公开(公告)号：US20220089710A1

公开(公告)日：2022-03-24

申请号：US17423690

申请日：2020-01-27

Applicant: Pfizer Inc.

Inventor： Christine Ruth WEST ,  Mark Thomas BROWN

IPC: C07K16/22 ,  A61P19/02 ,  A61B6/00 ,  A61K9/00

Abstract: The present invention relates to the treatment of signs and symptoms of osteoarthritis with an anti-nerve growth factor (NGF) antibody.

公开(公告)号：US20220071965A1

公开(公告)日：2022-03-10

申请号：US17415902

申请日：2019-12-17

Applicant: Pfizer Inc.

Inventor： Christine Ellen Bulawa ,  James Allan Fleming

IPC: A61K31/423 ,  C12N15/113 ,  A61K31/4245 ,  A61K31/4025 ,  C07K16/18 ,  A61P25/00

Abstract: The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a benzoxazole derivative transthyretin stabilizer or a pharmaceutically acceptable salt or prodrug thereof and an additional therapeutic agent for the treatment of transthyretin amyloidosis. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or a pharmaceutically acceptable salt or prodrug thereof and one or more additional therapeutic agent for the treatment of transthyretin amyloidosis.

公开(公告)号：US11267892B2

公开(公告)日：2022-03-08

申请号：US16255348

申请日：2019-01-23

Applicant: Pfizer Inc.

Inventor： Oi Kwan Wong ,  Joyce Ching Chou ,  Mathilde Brunnhilde Dusseaux ,  Julianne Smith ,  Barbra Johnson Sasu

IPC: A61K35/17 ,  C12N9/64 ,  A61K31/436 ,  C07K16/28 ,  C07K14/47 ,  C07K14/725 ,  A61K38/00 ,  A61K39/00

Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.

公开(公告)号：US11254668B2

公开(公告)日：2022-02-22

申请号：US16638271

申请日：2018-08-09

Applicant: Pfizer Inc.

Inventor： Brian Stephen Gerstenberger ,  Andrew Fensome ,  Dafydd Rhys Owen ,  Matthew Frank Brown ,  Matthew Merrill Hayward ,  Felix Vajdos ,  Li Huang Xing ,  Stephen Wayne Wright

IPC: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D519/00

Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.